Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 55,700 shares, a decline of 98.8% from the December 31st total of 4,710,000 shares. Based on an average daily volume of 7,300,000 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Leerink Partners dropped their price objective on Vincerx Pharma from $80.00 to $40.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Vincerx Pharma Stock Performance

Shares of VINC stock traded up $0.08 during trading hours on Friday, reaching $1.58. The company had a trading volume of 376,219 shares, compared to its average volume of 1,112,746. The firm has a market cap of $2.65 million, a PE ratio of -0.08 and a beta of 1.48. The business has a fifty day moving average price of $3.87 and a 200-day moving average price of $8.71. Vincerx Pharma has a one year low of $1.40 and a one year high of $187.44.

Institutional Investors Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its position in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 328,533 shares of the company’s stock after acquiring an additional 256,967 shares during the quarter. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent reporting period. 44.02% of the stock is owned by institutional investors.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.